Cargando…

Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients

Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we r...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadopoulos, Sotirios, Koulouris, Pantelis, Royer-Chardon, Claire, Tsoumakidou, Georgia, Dolcan, Ana, Cherix, Stephane, Matter, Maurice, Omoumi, Patrick, Digklia, Antonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984282/
https://www.ncbi.nlm.nih.gov/pubmed/35399933
http://dx.doi.org/10.3389/fendo.2022.794512
_version_ 1784682151829045248
author Papadopoulos, Sotirios
Koulouris, Pantelis
Royer-Chardon, Claire
Tsoumakidou, Georgia
Dolcan, Ana
Cherix, Stephane
Matter, Maurice
Omoumi, Patrick
Digklia, Antonia
author_facet Papadopoulos, Sotirios
Koulouris, Pantelis
Royer-Chardon, Claire
Tsoumakidou, Georgia
Dolcan, Ana
Cherix, Stephane
Matter, Maurice
Omoumi, Patrick
Digklia, Antonia
author_sort Papadopoulos, Sotirios
collection PubMed
description Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we report two cases of patients with desmoid tumors, treated with pazopanib and imatinib, who developed reactional lymphadenopathy. As this side effect is presented as a newly formed mass, it can result in new diagnostic questions and added imaging tests and can even lead to discontinuation of the treatment. This report may help the clinicians facing similar problems adopt a “watch and wait” approach.
format Online
Article
Text
id pubmed-8984282
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89842822022-04-07 Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients Papadopoulos, Sotirios Koulouris, Pantelis Royer-Chardon, Claire Tsoumakidou, Georgia Dolcan, Ana Cherix, Stephane Matter, Maurice Omoumi, Patrick Digklia, Antonia Front Endocrinol (Lausanne) Endocrinology Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we report two cases of patients with desmoid tumors, treated with pazopanib and imatinib, who developed reactional lymphadenopathy. As this side effect is presented as a newly formed mass, it can result in new diagnostic questions and added imaging tests and can even lead to discontinuation of the treatment. This report may help the clinicians facing similar problems adopt a “watch and wait” approach. Frontiers Media S.A. 2022-03-23 /pmc/articles/PMC8984282/ /pubmed/35399933 http://dx.doi.org/10.3389/fendo.2022.794512 Text en Copyright © 2022 Papadopoulos, Koulouris, Royer-Chardon, Tsoumakidou, Dolcan, Cherix, Matter, Omoumi and Digklia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Papadopoulos, Sotirios
Koulouris, Pantelis
Royer-Chardon, Claire
Tsoumakidou, Georgia
Dolcan, Ana
Cherix, Stephane
Matter, Maurice
Omoumi, Patrick
Digklia, Antonia
Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients
title Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients
title_full Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients
title_fullStr Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients
title_full_unstemmed Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients
title_short Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients
title_sort case report: tyrosine kinase inhibitors induced lymphadenopathy in desmoid tumor patients
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984282/
https://www.ncbi.nlm.nih.gov/pubmed/35399933
http://dx.doi.org/10.3389/fendo.2022.794512
work_keys_str_mv AT papadopoulossotirios casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients
AT koulourispantelis casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients
AT royerchardonclaire casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients
AT tsoumakidougeorgia casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients
AT dolcanana casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients
AT cherixstephane casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients
AT mattermaurice casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients
AT omoumipatrick casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients
AT digkliaantonia casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients